Elaine Warburton OBE Wins InspiringFifty Europe 2022 Award

Elaine Warburton OBE

NEWCASTLE UPON TYNE, UK, 14 June 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point-of-Need diagnostics, is pleased to announce that its Co-Founder and former CEO Elaine Warburton OBE, has been recognised as one of the top 50 women in tech in Europe through the  InspiringFifty Europe 2022 Award.

The InspiringFifty, run by EQL:HER, is a global initiative, on a mission to increase diversity in tech by recognising and amplifying the women excelling in science, technology, engineering, and mathematics (STEM) across the world.

This award demonstrates Elaine’s ambition as a healthcare and biotechnology entrepreneur. Elaine has taken QuantuMDx from concept to product, raising over £50m in both equity and grants. Since its inception, the company she co-founded has developed and commercialised its multiplex diagnostics platform, Q-POC™.

Building on Elaine’s work as Co-Founder, alongside Jonathan O’Halloran, current CEO, QuantuMDx has recently launched a SARS-CoV-2, Flu A/B & RSV Assay, a new testing panel that further expands the menu of testing available on the Q-POC™ platform. The panel provides differential diagnosis at the Point-of-Need and allows for rapid triage and treatment strategies, particularly in at-risk patient groups, in 35 minutes.

Elaine Warburton OBE, Co-Founder and Former CEO of QuantuMDx, and now Non-Executive Director of QuantuMDx said: “I was honoured to be in the Financial Times’ U.K. Inspiring 50 women in tech a few years ago and I am absolutely delighted to be recognised again in Europe. I would like to thank the team at QuantuMDx for their hard work and expertise in helping bring our vision and mission to life bringing people fast, accurate results at the Point-of-Need.”

Notes to editor:

About QuantuMDx

QuantuMDx is a progressive MedTech company passionate about empowering the world to control disease and reduce suffering. QuantuMDx solves real-world diagnostic problems by creating multiplex molecular solutions for the Point of Need.  

QuantuMDx has global operations and strategic partnerships – keeping it at the forefront of molecular diagnostics. 

Q-POC™ is a rapid, simple to use, portable, sample to answer multiplex PCR device. It has been designed for use in a range of real-world healthcare settings.

Q-POC™ and its first test, a SARS-CoV-2 multiplex detection assay, are CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within Europe. On 26th May Q-POC was CE marked under the IVDR and the assays were CE marked under the IVDD.

QuantuMDx plans to launch a range of syndromic multiplex testing assays over the coming months and years. 

For more information about QuantuMDx and Q-POC™, its rapid PCR point of care system, go to: www.quantumdx.com.  

InspiringFifty Initiative

InspiringFifty is a global initiative run by EQL:HER, with chapters across Europe, Africa, and North America. It’s focus is to increase diversity in tech, providing women in STEM with the recognition and platform they deserve, and inspiring the next generation of leaders and tech talent by providing positive role models across the tech ecosystem.

For media enquiries and interview requests:

Emma Long, Marketing Communications Manager, QuantuMDx, M: +44 (0) 7495 341 930  T: +44 (0) 870 803 1234  E: emma.long@quantumdx.com

Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications, +44 (0)20 3709 5700 / quantumdx@consilium-comms.com

For investor enquiries:

David Wilson, Nigel Barnes and Jeff Glushakow, WG Partners (Financial Adviser to QuantuMDx), +44 (0)20 3705 9330 / quantumdx@wgpartners.co.uk